CoChat

Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in Chile

Open access
Bueno, Susan M, Abarca, Katia, González, Pablo A, Gálvez, Nicolás M S, Soto, Jorge A, Duarte, Luisa F, Schultz, Bárbara M, Pacheco, Gaspar A, González, Liliana A, Vázquez, Yaneisi, Ríos, Mariana, Melo-González, Felipe, Rivera-Pérez, Daniela, Iturriaga, Carolina, Urzúa, Marcela, Domínguez, Angélica, Andrade, Catalina A, Berríos-Rojas, Roslye V, Canedo-Marroquín, Gisela, Covián, Camila, Moreno-Tapia, Daniela, Saavedra, Farides, Vallejos, Omar P, Donato, Paulina, Espinoza, Pilar, Fuentes, Daniela, González, Marcela, Guzmán, Paula, Muñoz Venturelli, Paula, Pérez, Carlos M, Potin, Marcela, Rojas, Álvaro, Fasce, Rodrigo A, Fernández, Jorge, Mora, Judith, Ramírez, Eugenio, Gaete-Argel, Aracelly, Oyarzún-Arrau, Aarón, Valiente-Echeverría, Fernando, Soto-Rifo, Ricardo, Weiskopf, Daniela, Sette, Alessandro, Zeng, Gang, Meng, Weining, González-Aramundiz, José V, Kalergis, Alexis M · 2022 · Clinical Infectious Diseases
Cited by 148

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Background: The development of effective vaccines against coronavirus disease 2019 is a global priority. CoronaVac is an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine with promising safety and immunogenicity profiles. This article reports safety and immunogenicity results obtained for healthy Chilean adults aged ≥18 years in a phase 3 clinical trial. Methods: Volunteers randomly received 2 doses of CoronaVac or placebo, separated by 2 weeks. A total of 434 volunteers were enrolled, 397 aged 18–59 years and 37 aged ≥60 years. Solicited and unsolicited adverse reactions were registered from all volunteers. Blood samples were obtained from a subset of volunteers and analyzed for humoral and cellular measures of immunogenicity. Results: The primary adverse reaction in the 434 volunteers was pain at the injection site, with a higher incidence in the vaccine than in the placebo arm. Adverse reactions observed were mostly mild and local. No severe adverse events were reported. The humoral evaluation was performed on 81 volunteers. Seroconversion rates for specific anti-S1-receptor binding domain (RBD) immunoglobulin G (IgG) were 82.22% and 84.44% in the 18–59 year age group and 62.69% and 70.37% in the ≥60 year age group, 2 and 4 weeks after the second dose, respectively. A significant increase in circulating neutralizing antibodies was detected 2 and 4 weeks after the second dose. The cellular evaluation was performed on 47 volunteers. We detected a significant induction of T-cell responses characterized by the secretion of interferon-γ (IFN-γ) upon stimulation with Mega Pools of peptides from SARS-CoV-2. Conclusions: Immunization with CoronaVac in a 0–14 schedule in Chilean adults aged ≥18 years is safe, induces anti-S1-RBD IgG with neutralizing capacity, activates T cells, and promotes the secretion of IFN-γ upon stimulation with SARS-CoV-2 antigens.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cid/ciab823

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

Metadata

Authors
Bueno, S. M., Abarca, K., González, P. A., Gálvez, N. M. S., Soto, J. A., Duarte, L. F., Schultz, B. M., Pacheco, G. A., González, L. A., Vázquez, Y., Ríos, M., Melo-González, F., Rivera-Pérez, D., Iturriaga, C., Urzúa, M., Domínguez, A., Andrade, C. A., Berríos-Rojas, R. V., Canedo-Marroquín, G., Covián, C., Moreno-Tapia, D., Saavedra, F., Vallejos, O. P., Donato, P., Espinoza, P., Fuentes, D., González, M., Guzmán, P., Muñoz Venturelli, P., Pérez, C. M., Potin, M., Rojas, Á., Fasce, R. A., Fernández, J., Mora, J., Ramírez, E., Gaete-Argel, A., Oyarzún-Arrau, A., Valiente-Echeverría, F., Soto-Rifo, R., Weiskopf, D., Sette, A., Zeng, G., Meng, W., González-Aramundiz, J. V., & Kalergis, A. M.
Venue
Clinical Infectious Diseases
Published
2021-09-19
Volume
75
Issue
1
Pages
e792-e804
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W3200692126
Cited by
148
References
13
FWCI
10.14
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.